Cemiplimab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Cemiplimab and local guidelines before prescribing.
Immune checkpoint inhibitor
Mechanism
PD-1 inhibitor.
Uses
Cutaneous squamous cell carcinoma, basal cell carcinoma, lung cancer.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Immune-related adverse events, rash, diarrhoea.
Interactions
Immunosuppressants reduce effect.
Contraindications and cautions
Autoimmune disease caution
Monitoring
TFT, LFT
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Immune toxicity pathway as other checkpoint inhibitors.
More from the textbook: uses, cautions and other points
- Treatment: Surgical excision (radiotherapy if surgery isn't possible); cemiplimab (PD-1 inhibitor) for advanced disease.
Oncology: Skin Cancer - Cemiplimab | Advanced cutaneous SCC.
Oncology: Skin Cancer - Advanced or metastatic (rare) - hedgehog pathway inhibitors ( vismodegib , sonidegib - teratogenic), cemiplimab.
Dermatology: Skin lesions and skin cancer - Advanced, inoperable or metastatic - cemiplimab (PD-1 inhibitor immunotherapy).
Dermatology: Skin lesions and skin cancer - Cemiplimab | Advanced cutaneous SCC (and BCC after hedgehog inhibitors).
Dermatology: Skin lesions and skin cancer - Anti-PD-1 - pembrolizumab , nivolumab , cemiplimab, dostarlimab.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology